Grifols plasma-derived medicines

Founded in Barcelona in 1909, Grifols has evolved from a small family-run clinical analysis laboratory into a premier global leader in healthcare and transfusion medicine. The company is world-renowned for its expertise in the development and production of plasma-derived therapies, which are essential for treating rare and life-threatening conditions such as primary immunodeficiencies and coagulation disorders.

From a manufacturing perspective, Grifols maintains a sophisticated vertical supply chain with significant industrial hubs in Spain and the United States. In recent years, the company has expanded its global footprint through strategic self-sufficiency projects in Egypt and Canada, ensuring stable regional access to life-saving proteins. The brand remains under the ultimate ownership of Grifols, S.A., which continues to be headquartered in Barcelona and listed on the NASDAQ and Spanish stock exchanges.